Optimization, validation, and comparison of a rapid method for the quantification of insulin-like growth factor 1 in serum using liquid chromatography-high-resolution mass spectrometry
- Authors
- Seo, Yoondam; Park, Jisoo; Kim, Minyoung; Sung, Changmin; Kwon, Oh-Seung; Lee, Hwa Jeong; Min, Hophil
- Issue Date
- 2021-02
- Publisher
- WILEY
- Citation
- DRUG TESTING AND ANALYSIS, v.13, no.2, pp.451 - 459
- Abstract
- Human insulin-like growth factor 1 (IGF-I) is the primary mediator of the effects of the growth hormone (GH). Therefore, it has been used as a biomarker to detect the abuse of GH in sports. The measurement of IGF-I relies on mass-based and immunological approaches to analysis. Among the mass-based analysis methods, liquid chromatography-mass spectrometry (LC-MS) has a number of functional advantages. LC-MS measurements based on the quantification of IGF-I, according to trypsin digestion, are used in the most common method of analyzing doping. However, this method is time-consuming and subject to experimental variability. In this study, we optimized a rapid method for detecting IGF-I without the trypsin digestion step. This method of analysis uses an ultra-centrifugal filter and an LC-HRMS through narrow-range mass scan method. To verify the validity of this method, eight categories of validation testing were applied with the following results: linearity, R-2 > 0.99; limit of detection, 15 ng/ml; limit of quantification, 20 ng/ml; accuracy, >99%; recovery rate, >95%; carryover, <0.03; and inter- and intra-day precision values, %CV < 2% and %CV < 6%, respectively. Furthermore, we discussed the correlation of the quantified concentration from two other methods, immunoradiometric assay (IRMA) and parallel reaction monitoring method, using 209 serum samples. In conclusion, although both mass spectrometry-based methods worked equally well in terms of analytical performance and correlation with IRMA results, narrow-range mass scan method had several advantages, such as time and cost savings and reliable reproducibility, over the existing methods.
- Keywords
- FACTOR-I; IGF-I; HORMONE; INTACT; AGREEMENT; doping control analysis; hGH biomarker; IGF‐ I; method validation; narrow‐ range mass scan
- ISSN
- 1942-7603
- URI
- https://pubs.kist.re.kr/handle/201004/117492
- DOI
- 10.1002/dta.2944
- Appears in Collections:
- KIST Article > 2021
- Files in This Item:
There are no files associated with this item.
- Export
- RIS (EndNote)
- XLS (Excel)
- XML
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.